Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
Titel:
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
Auteur:
Annala, M. Fu, S. Bacon, J.V.W. Sipola, J. Iqbal, N. Ferrario, C. Ong, M. Wadhwa, D. Hotte, S.J. Lo, G. Tran, B. Wood, L.A. Gingerich, J.R. North, S.A. Pezaro, C.J. Ruether, J.D. Sridhar, S.S. Kallio, H.M.L. Khalaf, D.J. Wong, A. Beja, K. Schönlau, E. Taavitsainen, S. Nykter, M. Vandekerkhove, G. Azad, A.A. Wyatt, A.W. Chi, K.N.